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Abstract: The aim of this review is to define the role of the combined dienogest (DNG)/  estradiol 
valerate (E2V) contraceptive pill, in terms of biochemistry, metabolic and   pharmacological 
effects and clinical application as well. E2V is the esterified form of 17β-estradiol (E2), while 
dienogest is a fourth-generation progestin with a partial antiandrogenic effect. The cycle stability 
is achieved with 2 to 3 mg DNG, supporting contraceptive efficacy. In this new oral contracep-
tive, E2V is combined with DNG in a four-phasic dose regimen (the first two tablets contain 
3 mg E2V; the next five tablets include 2 mg E2V + 2 mg DNG, followed by 17 tablets with 
2 mg E2V + 3 mg DNG; followed by two tablets with 1 mg E2V only, and finally two placebo 
tablets). Duration and intensity of scheduled withdrawal bleeding are lower with this   contraceptive 
pill, whereas the incidence and the intensity of intra-cyclic   bleeding are similar to the other oral 
contraceptive. With this new pill the levels of high density lipoprotein increased, while the levels 
of prothrombin fragment 1 + 2 and D-dimer remained relatively unchanged; the levels of sex 
hormone binding globulin, cortisol binding globulin, thyroxine binding globulin increased. The 
most frequently reported adverse events are: breast pain, headache, acne, alopecia, migraine, 
increase of   bodyweight. The satisfaction rate is about 79.4%.
Keywords: estradiol valerate, dienogest, combined oral contraceptive, four-phasic regimen, 
contraceptive safety
Introduction
Oral contraceptives were first approved for contraceptive use in the United States in 
1960, and are a very popular form of birth control as well as a widely accepted method 
of contraception. They are currently used by more than 100 million women worldwide 
and by almost 12 million women in the United States.1
Despite their undoubted popularity, some women experience adverse events while 
taking oral contraceptives, including breast tenderness, headache, nausea and loss of 
libido. In addition, epidemiological studies have suggested an association between oral 
contraceptive use and an increased risk of arterial and venous thrombotic events.2
In recent years, thanks to the availability of the new synthetic progestins as well 
as natural estrogens, new oral contaceptives showed high patient tolerance.
In May 2009, a new oral contraceptive became available in several European 
  countries and in July 2009 Bayer submitted Qlaira® to the US Food and Drug 
  Administration (FDA). Approval has been requested for two indications: oral 
  contraception and treatment of menorrhagia and/or   hypermenorrhea without organic 
pathology, in women   desiring oral contraception.International Journal of Women’s Health 2010:2 280
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In this oral contraceptive, estradiol valerate (E2V) is 
  combined with the progestin dienogest (DNG) in a four-pha-
sic dose regimen, incorporating an estrogen step-down and 
a progestin step-up over 26 days, with two more placebo 
tablets, making up a treatment of up to 28 days (Figure 1) 
The first two tablets contain 3 mg E2V to prime the endo-
metrium. The next five tablets include 2 mg E2V and 2 mg 
DNG followed by 17 tablets with 2 mg E2V and 3 mg DNG. 
Finally, there are two tablets with 1 mg E2V only and two 
placebo tablets.3
A continuous intake for 28 days has a double purpose:
1.  Optimization of the pharmacological profile,   maintaining 
stable plasma hormone levels¸ and consequently   reducing 
or eliminating catamenial symptoms (premenstrual 
  symptoms, headache, dysmenorrhea), associated with 
decreasing estrogen levels, thus improving general well-
being.5
2.  Improving adherence: the daily intake, without pauses, 
helps women to maintain a more regular intake,   avoiding 
the frequent omission that may otherwise reduce 
  contraceptive efficacy and increase adverse effects, such 
as intermenstrual spotting.5
The early estrogenic dominance guarantees the endome-
trial proliferation and sensitizes the tissue to the action of 
  progestin, while progestogenic dominance in the middle and 
at the end of the cycle, followed by a   moderate estrogenic 
activity in the final stage, ensure satisfactory   endometrial sta-
bility. The brief 2-day   interval without   hormones has proved 
to be enough to ensure regular bleeding in most of the women 
under Qlaira® treatment, compared with the conventional 
association of   ethinylestradiol (EE).6
The aim of this review was to define the role of the 
combined DNG/E2V contraceptive pill (Qlaira®; Bayer 
  Schering Pharma AG, Berlin, Germany) in terms of 
  biochemistry, metabolic and pharmacological effects, and 
clinical application, referring to recently published oral 
contraceptives trial data, performed on women aged 18 
and 50 years.
Pharmacokinetic profile
E2V
E2V (Figure 2) is the esterified form of 17β-estradiol (E2); it 
is rapidly and completely absorbed and hydrolyzed to natural 
estradiol (E2) during the first gastrointestinal tractpassage;6 
E2V is almost identical to E2 in terms of pharmacokinetics, 
and exactly identical in pharmacodynamics and clinically; 
E2V releases E2, which is identical to the endogenously 
produced E2; 1 mg of E2V is equivalent to 0.76 mg of E2, 
based on molecular weight.7
Absorption
E2V is completely absorbed by the intestinal mucosa and cleav-
age to estradiol and valeric acid during first liver-passage.3
Distribution
Thirty-eight percent of E2 is bound to sex hormone binding 
globulin (SHBG), 60% to albumin, and 2% to 3% circulates 
in a free form (induction of SHBG to 150% during a 28-
daily cycle).4
The serum E2 concentration remains stable during the 
28-day treatment period;8 the apparent volume of   distribution 
is ∼1.2 L/kg.3
Metabolism
Ninety-five percent is metabolized before entering the 
systemic circulation. Main metabolites are estrone, estrone 
sulfate and estrone glucuronide.4
2 28 26 24
placebo
3 mg
2 mg
1 mg
2 mg
3 mg DNG
E2V
DAY
PHASES 1 3 4
7
2
Figure 1 Dose regimen for Qlaira® (one cycle).  
Abbreviations: DNG, dienogest; E2V, estradiol valerate.International Journal of Women’s Health 2010:2 281
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Elimination
Terminal half-life is 13 to 20 hours due to enterohepatic 
recirculation and a large circulating pool of estrogen sulfates 
and glucuronides (90-min plasma half-life of circulating 
estradiol).4
Estradiol and its metabolites are predominately excreted in 
the urine. Minimal (∼10%) excretion occurs via the feces.3
DNG
DNG (Figure 3) has particular properties: it is similar to 
19-nortestosterone derivatives (Figure 4) with a short plasma 
half-life (11 hours), and has a strong progestational effect on 
the endometrium, high oral bioavailability (more that 90%); 
it is similar to progesterone derivatives with a relatively low 
inhibition of gonadotropin secretion, doses in milligram range, 
and anti-androgenic activity (40% of cyproterone acetate).9
Some specific properties of DNG are the absence of 
  interaction with specific transport proteins (SHBG, cortisol 
binding globulin [CBG]), and a high concentration of the 
unbound substance in serum: 10% unbound, 90% bound to 
albumin.10,11
Absorption
DNG is rapidly and almost completely absorbed with a 
bioavailability of ∼90%.4
Distribution
Ten percent of DNG is unbound, 90% is bound to albumin, 
with no binding to SHBG and CBG.3
Metabolism
DNG is completely metabolized by cytochrome P450 3A4 
(CYP3A4), hydroxylation and conjugation, mostly inactive 
metabolites. Unchanged DNG dominance is due to very quick 
excretion of metabolites.4
Elimination
DNG plasma half-life is approximately 11 hours. Only 1% 
of the unchanged drug is excreted; urinary to fecal   excretion 
ratio is 3:1, with 42% and 63% of an oral dose excreted 
renally within the first 24 hours and during the first 6 days.3 
Approximately, 86% of a DNG dose is excreted via the urine 
or feces in 6 days.3 The pharmacologically inactive metabo-
lites of DNG are rapidly excreted.3
Concomitant administration of DNG and CYP3A4 
  inducers may result in elevated DNG clearance rates.3 
  Concurrent treatments with CYP3A4 inhibitors may elevate 
plasma DNG concentration.3
The steady state is reached after 3 days which is not influ-
enced by SHBG levels. There is no relevant accumulation.4
Pharmacodynamic profile
E2 is considered weaker than EE in terms of hepatic 
protein synthesis induction, as demonstrated in clinical 
studies assessing SHBG, angiotensinogen and hemostatic 
  parameters.12–15
The DNG has a protective effect on the endometrium 
and the cycle stability is achieved with 2 to 3 mg DNG; 
the anti-estrogenic effect on the cervical mucus supports 
the   contraceptive efficacy; no relevant anti-estrogenic 
effect on vaginal epithelium is reported, while there is an 
anti-proliferative effect on endometriosis tissue.4
No clinically relevant effects have been observed with 
up to 20 mg/day DNG over 24 weeks on lipid metabolism, 
liver enzymes, hemostatic parameters and thyroid gland 
metabolism. In particular, DNG does not attenuate the 
estrogen-induced alterations in the hepatic production of 
hormone-sensitive proteins, including hemostatic factors, 
because of its anti-androgenic activity.16–19
In a prospective randomized study,20 the effect of E2-only 
therapy was compared to a combined E2/progestin treatment, 
regarding the excretion of vasoactive mediators, surrogating 
a possible effect on the vascular system. The progestin used 
was DNG, while the estrogen was E2V .20
Twenty-five women received E2V (2 mg/day) for 3 months 
and 27 women were treated with E2V (2 mg/day) combined 
with DNG (2 mg/day) in a continuing regimen.20
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Figure 3 Molecular structure of dienogest. International Journal of Women’s Health 2010:2 282
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E2V alone significantly increases the excretion of cyclic 
guanosine monophosphate (cGMP) and serotonin,   suggesting 
vasodilating effects. Furthermore, the prostacyclin/ 
thromboxane ratio, known to be crucial for the relationship 
between vasorelaxation and vasoconstriction, increased as 
well. No significant changes were found for urodilatin, which 
is known to elicit different effects on the cardiovascular and 
renal systems, respectively.20
Combined E2V/DNG therapy also led to significant 
increases in cGMP and serotonin excretion, suggesting that 
progestin addition for 3 months does not affect these   markers. 
However, in contrast to estrogen-only treatment, there was 
no significant increase in the prostacyclin/  thromboxane 
ratio, which can be explained by the antagonistic action 
of the progestin. The excretion of urodilatin significantly 
increased, probably due to the counterbalancing   progestin 
effects on the renal vascular system.20 In conclusion, the 
changes in   vasoactive markers suggest a potential   estrogenic 
  vasorelaxant effect. Since there were no   significant 
  differences between the two groups, possible vascular effects 
of DNG, evaluated for the first time, might not be of   clinical 
relevance, at least not on women without cardiovascular 
diseases.20
Interactions
Two studies21 investigated the effects of CYP3A4 induction 
(study 1; E2V/DNG on days 1 to 17, rifampicin 600 mg on 
days 12 to 16 [n = 16]) and inhibition (study 2; E2V/DNG 
on days 1 to 14, ketoconazole 400 mg or erythromycin 
500 mg 3 times daily on days 8 to 14 [n = 24]) on the phar-
macokinetic profiles of E2 and DNG in healthy post-meno-
pausal women. With rifampicin, the geometric mean ratios 
(day 17 vs 11) of E2 AUC (0 to 24 hours) and Cmax were 
56% (90% CI 53.1% to 59.8%) and 75% (66.9%–84.4%), 
  respectively. The   corresponding ratios for DNG were 17% 
(15.6% to 18.7%) and 48% (44.8% to 51.6%), respectively. 
With ketoconazole, the geometric mean ratios (day 14 vs 
7) of E2 AUC (0 to 24 hours) and Cmax were 157% (145% 
to 171%) and 165% (149% to 182%), respectively. The 
  corresponding ratios for DNG were 286% (263% to 311%) 
and 194% (184% to 205%), respectively. With erythro-
mycin, the ratios for E2 were 133% (118% to 150%) and 
151% (136% to 168%), respectively, and the ratios for DNG 
were 162% (146% to 180%) and 133% (123% to 144%), 
respectively.   Therefore, there is a   significant interaction 
between inducers and   inhibitors of CYP3A4 activity and 
E2V/DNG.21
Efficacy
Inhibition of ovulation
Natural E2 has proved to be unsatisfactory in respect to cycle 
control. To investigate this aspect, two randomized, open 
label, Phase II studies were carried out with the purpose of 
identifying the optimal dose of E2V and DNG, as well as the 
duration of their intake during a 28-day cycle.
The first study compared two regimens (regimens 1A 
and 2A)22 with similar dosages of DNG, but with a   different 
  duration of administration. Having established in the first 
PROGESTOGENS
C-21 progestogens C-19 nortestosterone Spirolactone
Pregnanes Gonanes Drospirenone
• MPA
• Megestrol acetate
• Cyproterone acetate
• Trimegestone
• Norethindrone
• Norethindrone acetate
• Ethynodiol diacetate
• Lynestrenol
• Norethynodrel
• Dienogest
• Norgestrel
• Levonorgestrel
• Norgestimate
• Desogestrel
• Gestodene
Estranes
Figure 4 Classification of progestogens.International Journal of Women’s Health 2010:2 283
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study that the duration of application of regimen 2A was most 
  suitable, but that the dosages of DNG were too low for effective 
ovulation inhibition, a second study,   comparing two regimens 
(regimens 2B and 2C) with similar duration of treatment, but 
with increased dosages of DNG, was undertaken.22
Indeed, as DNG does not contain any ethinyl group, 
the absence of this inhibitory mechanism could explain 
the relatively short half-life and the higher dose necessary 
for ovulation inhibition of DNG compared to, for example, 
levonorgestrel (LNG).23
Both studies were carried out to evaluate ovulation 
inhibition, which was assessed by transvaginal ultrasound 
monitoring of follicle size and analysis of serum E2 and 
progesterone levels, and classified according to the 6-point 
scoring system of Hoogland and Skouby.24
The primary efficacy end point in both studies was the 
proportion of women with a Hoogland score of 5 (luteinized 
unruptured follicle) or a Hoogland score of 6 (  ovulation) at 
cycle 2.22 A Hoogland score of 6 is defined as a   ruptured 
  follicle-like structure (FLS) of 13 mm with serum 
  progesterone of 5 nmol/L and E2 of 0.1 nmol/L. A Hoogland 
score of 5 was considered as critical as a Hoogland score of 
6, since a persisting FLS may still develop into a ruptured 
FLS in subsequent cycles.22
In studies 1 and 2, 192 and 203 women were analyzed, 
respectively. In study 1, 10 women (10.9%) in regimen 
1A and six women (6.4%) in regimen 2A had a Hoogland 
score of 5 or 6. In study 2, three women (3.1%) in regimen 
2B and one woman (1.0%) in regimen 2C had a Hoogland 
score of 5 or 6. There were no safety concerns with any of 
the regimens.22
The results of these studies identified a four-phasic 
oral contraceptive preparation comprising E2V/DNG that 
  provides efficient ovulation inhibition.22
The studies were performed in a stepwise manner in order 
to determine, firstly, a suitable duration of treatment (study 1) 
and, secondly, a suitable dose of DNG (study 2) for effective 
ovulation inhibition.22 Each step increased the ovulation-
inhibition potency remarkably, with the result that regimen 2B 
(with E2V 3 mg in days 1 to 2, E2V 3 mg/DNG 2 mg in days 
3 to 7, E2V 2 mg/DNG 3 mg in days 8 to 24 and E2V 1 mg in 
days 27 to 28) proved to be capable of guaranteeing the best 
contraceptive efficacy and safety in Phase III   studies.22 This 
formulation contained the lowest dose of DNG that inhibited 
more than 95% of ovulations in cycle 2.22
A large multicenter study recruited 1377 women for 
20 cycles of follow-up. The corrected Pearl Index (PI) for 
all those entering the study was 0.34, with Qlaira® being 
equally effective in those over 35 and under 35.25 A further 
study comparing Qlaira® with a 21/7 20 µg EE/100 µg LNG 
pill (Miranova®) resulted in just one method failure (in the 
Miranova® group).7
Nevertheless, Qlaira® has a similar PI to conventional 
pills and its bleeding pattern in general is similar to that with 
a 20 µg EE/100 µg LNG pill.25
Bleeding parameters and cycle control
The early estrogen dominance guarantees the initial 
  endometrial proliferation and sensitizes the tissue to the action 
of progestogens. The Qlaira® regimen with the   dominance of 
DNG in the middle and the later part of the cycle, followed 
by a moderate estrogenic activity during the final part of the 
cycle, ensures an acceptable endometrial stability.6 Instead, the 
use of E2 as a part of a monophasic or a biphasic regimen has 
a poor cycle control.26–28 In a randomized, double-blind study, 
E2V/DNG and EE/LNG demonstrated an acceptable bleeding 
pattern and cycle control, according to several co-primary 
endpoints, in 798 women aged 18 to 50 years (399 in each 
treatment group), who received seven cycles of E2V/DNG or 
EE/LNG.7 The primary efficacy endpoints were the   number 
of days and episodes of bleeding/spotting for a 90-day period, 
the length of the bleeding/spotting episodes and the incidence 
and characteristics of scheduled (  withdrawal) and unscheduled 
(intracyclic) bleeding for cycle.7
In particular, withdrawal bleeding was experienced by 
significantly (P  0.0001 for each cycle) fewer E2V/DNG 
recipients (77.7% to 83.2%) than EE/LNG recipients 
(89.5% to 93.8%) over seven cycles, with a mean absence 
of   withdrawal bleeding in 19.4% (range 16.8% to 22.3%) vs 
7.7% (range 6.2% to 10.5%) of women.7 The absence of 
  withdrawal bleeding was experienced at least once over 
the seven cycles by 56.9% and 37.8% of women receiving 
E2V/DNG and EE/LNG, with 21.2% and 22.2%   experiencing 
the absence of withdrawal bleeding once and 12.2% and 7.1% 
  experiencing the absence of withdrawal bleeding twice.7 An 
absence of all withdrawal and intracyclic bleeding occurred 
in 15.4% and 4.5% of cycles with E2V/DNG and EE/LNG.7 
The mean length of withdrawal bleeding was significantly 
(P  0.05) shorter in E2V/DNG recipients (4.1 to 4.7 days) 
than EE/LNG recipients (5.0 to 5.2 days).7 In a descriptive 
analysis, 56.3% to 62.5% and 37.5% to 43.8% of women in 
the respective treatment groups experienced ‘spotting’ and/or 
‘light bleeding’ (data derived from a graph).7 A significant 
difference (P-value not reported) in the maximum intensity 
of withdrawal bleeding was observed between E2V/DNG 
and EE/LNG therapy; mean maximum intensity withdrawal International Journal of Women’s Health 2010:2 284
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bleeding scores were 3.2 to 3.3 per cycle with E2V/DNG and 
3.6 per cycle with EE/LNG.7 From the end of the exposure to 
the progestogen component, the median onset of   withdrawal 
bleeding was days 2 to 3 with E2V/DNG and day 3 with 
EE/LNG.9
For instance, no significant difference in the incidence of 
intracyclic bleeding over seven cycles was observed between 
the E2V/DNG (10.5% to 18.6% of women) and EE/LNG 
(9.9% to 17.1%) groups in the double-blind study, with a 
heavier intensity observed less often with E2V/DNG than 
with EE/LNG (mean 2.4% vs 4.0% of women).7
Average hemoglobin levels remained unchanged 
  throughout the treatment in both groups.7 There was one 
unintended pregnancy attributed to method failure, during 
the treatment in a woman who received EE/LNG.7
In another non-comparative, multicenter study, in which 
1391 women were enrolled (1377 comprised the full analysis 
set and 1074 completed treatment), E2V/DNG demonstrated 
a high contraceptive efficacy.29 Six of the pregnancies were 
attributed to method failure, resulting in an adjusted PI, 
based on 1786.5 women-years of exposure, of 0.34 (upper 
limit of 95% CI 0.73).29 In a subset of women aged 18 to 
35   participating in this study, 12 pregnancies occurred, five 
of which were attributed to method failure; the unadjusted 
PI, based on 1277.5 women-years of exposure, was 0.94 
(upper limit of 95% CI 1.65), while the adjusted PI, based on 
1268.5 women-years of exposure, was 0.40 (upper limit of 
95% CI 0.92).29 The Kaplan–Meier estimate of the   cumulative 
pregnancy rate for this subset of women was 0.0142 (95% 
CI 0.0080 to 0.0251).29
Moreover withdrawal bleeding was generally stable 
throughout this study, with 76.8% to 81.6% of women 
experiencing withdrawal bleeding during cycles 1 to 19 of 
E2V/DNG therapy, although the intensity and duration of 
withdrawal bleeding progressively decreased with treatment 
(no data or statistical analysis reported).29
A minority of women experienced intracyclic bleeding in 
the double-blind7 and non-comparative29 studies.
Metabolism
Various  hormone  parameters  and  serum-binding 
  globulins were investigated in a double-blind, controlled, 
  randomized, four-arm, bicentric clinical study.30 Four groups 
with 25 volunteers each, were treated for six cycles with 
  monophasic combination containing 21 tablets with either 
30 µg EE + 2 mg DNG, 20 µg EE + 2 mg DNG, 10 µg 
EE + 2 mg E2V + 2 mg DNG, or 20 µg EE + 100 µg LNG. 
The DNG-containing oral contraceptives caused a higher 
increase in SHBG and   thyroxine binding globulin (TBG) 
levels than the LNG-containing preparation. There was a 
reduction of dehydroepiandrosterone sulfate throughout the 
study in all treatment groups, which appeared to be enhanced 
with the increasing length of treatment.30
There was a rise in CBG in all groups, which was most 
pronounced in women treated with 30 EE/DNG (+90%) and 
least with EE/E2V/DNG (+55%), indicating a minor hepatic 
impact of 2 mg E2V compared to 20 or 30 µg EE, and no 
effect of the progestogen component. It is known that the 
treatment with low-dose oral contraceptives generally does 
not influence prolactin levels,31–35 except from a sporadic and 
transitory hyperprolactinemia in predisposed women.36,37
In contrast to EE, the use of E2V in oral contraceptives 
seemed to cause a time-dependent significant rise in prolactin 
levels that was 40% higher after six treatment cycles, while 
the cycle control was better with the oral contraceptives 
containing 30 µg EE30 (Table 1).
Another single center, open-label, randomized controlled 
trial was performed to compare the metabolic effects of a new 
four-phasic oral contraceptive comprising E2V and DNG with 
EE and LNG. Women aged 18 to 50 years received, for seven 
cycles, a four-phasic regimen   containing DNG (2 days E2V 
3 mg, 5 days E2V 2 mg/DNG 2 mg, 17 days E2V 2 mg/DNG 
3 mg, 2 days E2V 1 mg, 2 days placebo; n = 30) or a sequential 
regimen of EE and LNG (6 days EE 0.03 mg/LNG 0.05 mg, 
5 days EE 0.04 mg/LNG 0.075 mg, 10 days EE 0.03 mg/LNG 
0.125 mg, 7 days placebo; n = 28).38 The main efficacy vari-
able was the   individual-specific   relative   variation in high-den-
sity lipoprotein and low-density lipoprotein   cholesterol from 
baseline to cycle 7.38 Hemostatic parameters, carbohydrate 
metabolism and hormone levels were also investigated.38 The 
change in high-density lipoprotein cholesterol was +7.9% ± 
21.8% for women using E2V and DNG and −2.3% ± 14.4% 
for EE and LNG (P = 0.055). The corresponding changes 
for low-density lipoprotein   cholesterol were −6.5% ± 15.9% 
and −3.0% ± 17.4%, respectively (P = 0.458).38 In general, 
variations in hemostatic features were less pronounced with 
E2V and DNG than with EE and LNG.38 The carbohydrate 
metabolism pattern remained unchanged and within the 
normal limits in both groups. SHBG levels increased by 
+62.7% ± 50.5% and +111.6% ± 48.0% for women using 
E2V and DNG, compared to EE and LNG, respectively.38 
Oral contraceptive containing E2V and DNG demonstrated 
a more favorable effect on lipid profiles and had a slight 
impact on hemostatic parameters compared with EE and 
LNG. No clinically important changes in metabolic features 
were observed in both treatment groups38 (Table 2).International Journal of Women’s Health 2010:2 285
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Coagulation disorders
One of the most relevant complications of oral   contraceptive 
use is thromboembolic disease, and the relative risk of deep 
vein thrombosis (DVT) rises especially during the first year 
of use, suggesting an important role of predisposition and 
risk factors.39–42
Nevertheless, DVT is a rare event in young women, and 
consequently fairly reliable epidemiological findings   cannot 
be expected before new formulations have been used by 
a large number of women for a sufficient period of time. 
As a surrogate, regulatory authorities require controlled 
  studies on the effect of new oral contraceptive   formulations 
or regimens on hemostatic parameters, even though no 
causal   relationship has so far been established between 
oral   contraceptive-induced changes in distinct hemostatic 
parameters and the risk of venous thromboembolic events 
(VTEs).43
The decrease in the incidence of VTEs after   introduction 
of low-dose oral contraceptives containing 35 µg EE 
  suggested a causal association with the estrogen dose.39,44–46 
This might be possible because changes in coagulation 
and fibrinolysis cascade were significantly lower with 
30 µg EE containing COs than with 50 µg EE.47 Therefore, 
  development of new oral contraceptive formulation was 
characterized by a reduction in EE dose to 20 µg, which 
had to be compensated by more potent progestins, in order 
to maintain the contraceptive efficacy.13
In an open-label study,38 Qlaira® was compared with 
Logynon® (triphasic EE/LNG oral contraceptives) in terms 
of plasma lipids and hemostatic parameters over seven cycles. 
It was found that levels of prothrombin fragment 1 + 2, and 
D-dimer remained relatively unchanged with E2V/DNG.
In a further open-label crossover study,48 women aged 
18 to 50 years were randomized to receive the four-phasic 
oral contraceptive containing E2V/DNG or a monophasic 
oral contraceptive containing EE 0.03 mg/LNG 0.15 mg, 
in order to compare the hemostatic effects. Women received 
each treatment for three cycles, with two washout cycles 
between treatments. The primary efficacy variables were 
the intra-individual absolute changes in prothrombin frag-
ment 1 + 2 and D-dimer from baseline to cycle 3.   Secondary 
  efficacy variables included the intra-individual absolute 
changes in procoagulatory and anticoagulatory parameters 
from   baseline to cycle 3. Data from 29 women were assessed. 
Overall, changes in hemostatic parameters from baseline 
to cycle 3 were generally less evident with E2V/DNG 
than with EE/LNG.48 The intra-individual absolute change 
in   prothrombin fragment 1 + 2 was +0.00 ± 0.04 nmol/L 
with E2V/DNG, compared with +0.03 ± 0.16 nmol/L with 
EE/LNG (P = 0.43). The intra-individual absolute change 
in D-dimer with E2V/DNG was +38.9 ± 129.9 ng/mL, 
which was   significantly lower (P = 0.01) than the change 
with EE/LNG (+157.9 ± 198.3 ng/mL).48 The intra-indi-
vidual absolute change in prothrombin (factor II) was less 
  pronounced with E2V/DNG (+10.4% ± 17.5%) vs EE/LNG 
(+24.0% ± 13.0%).48 Changes in procoagulatory parameters 
were generally less pronounced with E2V/DNG than with 
EE/LNG.48 The intra-individual absolute change in fibrinogen   
Table 1 Metabolic changes from E2V/DNG compared to EE/DNG and EE/LNG
Oral contraceptives
30 µg EE/2 mg DNG 20 µg EE/2 mg DNG 10 µg EE/2 mg E2V/2 mg DNG 20 µg EE/100 mg LNG
SHBG ++ ++ ++ +
TBG ++ ++ ++ +
DHEAS − − − − − − − −
CBG +++ ++ + ++
PRL stable stable ++ stable
time dependent
Abbreviations: EE, ethinylestradiol; DNG, dienogest; E2V, estradiol valerate; LNG, levonorgestrel; SHBG, sex hormone binding globulin; DHEAS, dehydroepiandrosterone 
sulfate; CBG, cortisol binding globulin; PRL, prolactin.
Table 2 Metabolic change from E2V/DNG compared to 
EE/LNG
Oral contraceptives
E2V/DNG EE/LNG P value
HDL +7.9 ± 21.8% −2.3 ± 14.4% 0.055
LDL −6.5 ± 15.9% −3.0 ± 17.4% 0.458
SHBG 62.7 ± 50.5% 111.6 ± 48% –
Prothrombin  
fragment 1 + 2
stable stable
D-dimer stable stable
Abbreviations: E2V, estradiol valerate; DNG, dienogest; EE, ethinylestradiol; 
LNG, levonorgestrel; HDL, high-density lipoprotein; LDL, low-density lipoprotein; 
SHBG, sex hormon binding globulin.International Journal of Women’s Health 2010:2 286
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was +0.3 ± 1.5 g/L with E2V/DNG vs +0.8 ± 1.1 g/L with 
EE/LNG.48 Corresponding values for factor VII activity were 
+2.3% ± 17.2% and +6.8% ± 14.2%, respectively. Almost 
no variation in Factor VIII activity was observed with either 
E2V/DNG (−1.3% ± 12.9%) or EE/LNG (+2.6% ± 12.2%).48 
Changes in anticoagulatory   parameters were minimal, but 
tended to be less pronounced with E2V/DNG than with EE/
LNG.48 Antithrombin III activity remained stable with E2V/
DNG and EE/LNG, with the intra-individual absolute change 
being −0.3% ± 6.5% and −3.0% ± 6.7%, respectively.48 
Changes in protein C and protein S   activity were minimal 
with E2V/DNG (−2.3% ± 14.1% and +4.5% ± 11.0%, 
respectively) and EE/LNG (+5.7% ± 13.6% and −0.8% ± 
20.6%,   respectively).48 Activated protein C (APC) resis-
tance remained unchanged during the treatment with E2V/
DNG (−0.04 ± 0.28) and EE/LNG (−0.08 ± 0.40). Almost 
no change was registered in APC sensitivity with E2V/
DNG (+0.09 ± 0.43), but a slight increase with EE/LNG 
(+0.6 ± 0.7).48 Indeed, the   innovative four-phasic oral 
  contraceptive composed of E2V/DNG was well-tolerated and 
had less   pronounced effects on hemostatic parameters than 
a monophasic oral contraceptive composed of EE/LNG.48 
These findings are consistent with those observed in a study 
comparing E2V/DNG with a triphasic regimen of EE/LNG,38 
suggesting that E2V/DNG has a minor impact on hemostatic 
parameters compared with EE/LNG48 (Table 3).
A specific study43 was carried out to investigate the effect 
of an oral contraceptive containing 30 µg EE and 2 mg 
DNG with two different regimens on various hemostatic 
  parameters. Hemostatic parameters were measured in 59 
women treated with a monophasic oral contraceptive   containing 
30 µg EE + 2 mg DNG either conventionally (13 cycles with 
21 days of treatment + 7 days without hormones) or with an 
extended-cycle regimen (four extended cycles with 84 days 
of continuous administration of EE/DNG + 7 days without 
hormones).43 Blood samples were taken on days 21 to 26 of the 
previous control cycle and on days 19 to 21 of the 3rd and 13th 
conventional cycle, or on days 82 to 84 of the first and fourth 
extended cycle.43 After 3 and 12 months, important increases 
in fibrinogen (20%), factor VII antigen (50% to 60%), factor 
VII activity (45%), activated factor VII (30% to 45%) and 
factor VIII activity (10% to 20%) took place in both treatment 
regimens. In both groups, there was a slight but significant fall 
in the level and activity of antithrombin, a 20% to 25% decrease 
in total and free protein S and a 15% to 20% increment in the 
level and activity of protein C, but no relevant variation of the 
thrombin–antithrombin complex. A significant rise over time of 
about 25% of prothrombin fragment 1 + 2 occurred only in the 
extended-cycle group, but this effect did not change significantly 
from that observed during conventional treatment. Plasminogen 
increased by 50% in both groups, while tissue-plasminogen 
activator (t-PA) activity rose by 15% in the   conventional group 
and by 25% to 30% in the extended-cycle group. In both groups, 
t-PA antigen was diminished by about 30% and plasminogen 
activator inhibitor (PAI)-1 by 40% to 60%. The levels of the 
plasmin–antiplasmin complex increased by 30% to 40% and 
those of D-dimers by 20% to 55%. The prothrombin time was 
slightly increased and the activated partial thromboplastin time 
was slightly decreased.43
This study clearly demonstrated that there is no significant 
difference between the conventional and the extended-cycle 
regimen with respect to any hemostatic parameters at any 
time, during treatment with EE/DNG.
This is the first double-blind, controlled,   randomized study 
to compare the effect of different estrogen   components in 
oral contraceptives on hemostatic parameters. Four groups of 
25 women each were treated for six cycles with   monophasic 
  combinations containing 21   tablets with either 30 µg EE + 2 mg 
DNG, 20 µg EE + 2 mg DNG, 10 µg EE + 2 mg E2V + 2 mg 
DNG, or 20 µg EE + 100 µg LNG. Blood samples were taken 
on days 21 to 26 of the control cycle and on days 18 to 21 of 
the first, third and sixth   treatment cycle.   Treatment with all 
four oral   contraceptives provoked an increase in fibrinogen 
levels, prothrombin fragment 1–2, D-dimer, plasminogen, and 
plasmin-antiplasmin complex and protein C activity, a lower 
antithrombin activity, t-PA and PAI, and a small decrease in 
the sensitivity to activated   protein C, but no relevant change 
Table 3 Hemostatic parameters change from E2V/DNG compared 
to EE/LNG
Oral contraceptive
E2V/DNG EE/LNG
Prothrombin  
fragment 1 + 2
+0.00 ± 0.04 nmol/L +0.03 ± 0.16 nmol/L
D-dimer +38.9 ± 129.9 ng/mL +157.9 ± 198.3 ng/mL
Prothrombin +10.4 ± 17.5% +24 ± 13%
Fibrinogen +0.3 ± 1.5 g/L +0.8 ± 1.1 g/L
Factor VII +2.3 ± 17.2% +6.8 ± 14.2%
Factor VIII −1.3 ± 12.9% +2.6 ± 12.2%
Antithrombin III −0.3 ± 6.5% −3.0 ± 6.7%
Prot C −2.3 ± 14.1% +5.7 ± 13.6%
Prot S +4.5 ± 11.0% −0.8 ± 20.6%
APC −0.04 ± 0.28 −0.08 ± 0.40
APC sensitivity +0.09 ± 0.43 +0.6 ± 0.7
Abbreviations: E2V, estradiol valerate; DNG, dienogest; EE; ethinylestradiol; 
LNG, levonorgestrel;   APC, activated protein C.International Journal of Women’s Health 2010:2 287
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in the thrombin–antithrombin complex. The results, which 
revealed a rise in protein C activity by 10% to 15% of women 
during use of all four formulations, are in accordance with 
findings of previous oral contraceptive studies.16,49–58 The 
effects of EE/E2V/DNG on total and free protein S and on 
t-PA and PAI were lower compared to 20 µg EE + 2 mg DNG 
effects, suggesting that the impact of 2 mg E2V on several 
hemostatic parameters is not as much that of 10 µg EE. The 
fall of total and free protein S observed in the present study 
with the DNG-containing oral contraceptives was also in the 
range of the results of previous studies.49–61
The results show an antagonistic effect of LNG on the 
EE-induced rise of factor VII activity and fragment 1 + 2 and 
on the EE-dependent reduction of total and free protein S.13
In the previous study, no significant differences between 
the four formulations were observed in their effect on most 
hemostatic parameters, except those on total and free protein S, 
and on factor VII in cycle 6. In fact, total and free protein S 
decreased according to the EE dose during treatment with oral 
contraceptives containing DNG, and the effect of EE/E2V/DNG 
was less compared to that of 20 EE/DNG. The results suggest 
that 10 µg EE combined with DNG exerts a stronger effect on 
some hemostatic parameters than 2 mg E2V .13
Safety
Adverse events and tolerability
A randomized comparative trial7 reported adverse reactions 
in 10.0% and 8.5% of women receiving E2V/DNG and 
EE/LNG, respectively. The most common adverse events 
were breast pain, headache, acne, alopecia, migraine and an 
increase of bodyweight.7 The most frequent adverse events 
in women treated with E2V/DNG were breast pain (3.8%), 
headache (2.5%), and vaginal infection (2.5%), while the most 
frequently reported adverse events in women treated with EE/
LNG were acne (3.3%), headache (3.3%), and nasopharyngi-
tis (1.8%). The incidence of dysmenorrhea in the preceding 
6 months was 9.5% in the E2V/DNG group, and 6.8% in the 
EE/LNG group, but during the study, the reported incidence 
of dysmenorrhea was 0.5% in both   treatment groups.7
The frequency (10.0% vs 8.5%) and nature of   treatment-
related adverse events was generally similar between 
the E2V/DNG and EE/LNG treatment groups.7 Serious 
adverse events occurred in four E2V/DNG recipients and 
three EE/LNG recipients. None of the serious adverse events 
reported were deemed to be related to the study medication, 
apart from a ruptured ovarian cyst, autonomic nervous system 
imbalance (one E2V/DNG recipient) and breast cancer (one 
EE/LNG recipient).7 No deaths were reported.7
Endrikat et al22 reported only one serious adverse event 
in a woman in study 1 (regimen 1A) considered possibly 
treatment related (ovarian cyst). No deaths occurred dur-
ing the   studies.22 In study I, four women had adverse events 
considered   possibly related to treatment that resulted in study 
discontinuation (regimen 1A, n = 2 [ovarian cyst, breast 
pain]; regimen 2A, n = 2 [edema, diarrhea]).22 Eight women 
in study 2, had   treatment-related adverse events that resulted 
in   discontinuation of treatment (regimen 2B, n = 5 [  depression, 
headache, worsening acne, eye irritation, furunculousis]; 
  regimen 2C, n = 3 [emotional liability, n = 2, headache]).22
In the non-comparative study, treatment-related adverse 
events occurred in 272 women (19.8%).29
The most frequently reported treatment-emergent 
adverse events in women aged 18 to 50 years in the 
pooled   analysis (n = 2266) were breast discomfort (4.9% 
of women),   metrorrhagia (4.9%) and headache (3.1%).62 
Other   treatment-emergent adverse events occurring in 
1% of women included acne (2.8% of women), increase 
in   bodyweight (1.5%), amenorrhea (1.7%), dysmenorrhea 
(1.7%) and abdominal pain (1.7%).62
In the study by Parke et al48 the proportion of women 
reporting adverse events was generally similar in both treat-
ment groups. No adverse events were rated as serious.48
Satisfaction
In the open-label 20-cycle study (n = 1377), 79,5% of women 
were either satisfied or very satisfied with Qlaira®, and just 
over two-thirds of the full analysis set would consider taking 
Qlaira® in the future. Only 7.4% were dissatisfied or very 
dissatisfied. One hundred and forty-two women complained 
because of adverse events but only 37 discontinued use 
because of irregular menstrual bleeding.29
In the study by Ahrendt et al,7 79.4% of women were 
satisfied with E2V/DNG and 79.9% with EE/LNG; 39.8% 
of women were very satisfied with E2V/DNG and 35.3% of 
women were very satisfied with EE/LNG.
Contraindications
E2V/DNG is contraindicated only in women with an 
acquired or hereditary predisposition for arterial or 
venous   thrombosis; a history of or current episodes of 
  arterial   thrombosis,   cerebrovascular accident, liver cancer, 
  pancreatitis (if   associated with severe hypertriglyceridemia), 
severe hepatic disease or venous thrombosis; a history of 
migraine with focal neurological symptoms; hypersensitivity 
to the active   substances or to any of the excipients; known 
or suspected sex-steroid influenced cancer; the presence of International Journal of Women’s Health 2010:2 288
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severe or multiple arterial or venous thrombosis risk factors, 
  including diabetes mellitus with vascular symptoms, severe 
  dyslipoproteinemia and severe hypertension or undiagnosed 
vaginal bleeding.3
Discussion
The dose of EE has been progressively reduced over time, 
and contraceptives containing 20 µg or even 15 µg of EE 
are currently available. However, EE dose will be unlikely 
to be further reduced, due to the possible occurrence of 
symptoms of low estrogen levels.63 Furthermore, some 
studies have suggested that a daily dose of 10 µg may 
have unfavorable impact on hemostatic parameters.14 The 
  objective was to develop hormonal contraceptives containing 
natural   estrogens like E2, which is structurally identical to 
endogenous estradiol.
DNG was included as the progestin component, as 
it is known to have a relevant protective function on 
the   endometrium,64 it is well tolerated and associated 
with   excellent contraceptive efficacy when combined with 
EE.65–68 However, previous attempts to replace EE with E2 
proved to be somewhat unsatisfactory with respect to cycle 
  control,26–28 particularly when E2 was administered as part 
of a   monophasic or a biphasic regimen. Therefore,   previous 
studies, which were carried out in an iterative stepwise 
manner, have shown that the current regimen (E2V 3 mg 
for 2 days, followed by E2V/DNG 2 mg/2 mg for 5 days, 
E2V/DNG 2 mg/3 mg for 17 days, E2V 1 mg for 2 days 
and placebo for 2 days) contains the optimal dose of DNG 
  necessary for efficient ovulation inhibition when combined 
with E2V .7 The dynamic dosing regimen was designed to 
ensure   estrogen dominance in the first part of the cycle 
and progestin   dominance in the middle to the later part of 
the cycle, thereby optimizing the bleeding   pattern. Early 
  estrogenic dominance is hypothesized to ensure   initial 
  endometrial proliferation and severity for mid-cyclic 
  progestin action and endometrial stroma stability, particularly 
towards the end of the cycle.7
Women who received E2V/DNG have fewer bleeding/
spotting days and fewer bleeding/spotting   episodes than 
women who received EE/LNG; accordingly, an absence of 
withdrawal bleeding in cycles 1 to 7 occurred more often 
in women treated with E2V/DNG than with EE/LNG. Over 
seven cycles of treatment, the mean length of   withdrawal 
bleeding was slightly shorter in women treated with E2V/
DNG compared with women treated with EE/LNG; and the 
maximum intensity of withdrawal   bleeding was more often 
spotting and light bleeding in women treated with E2V/DNG. 
Conversely, the maximum intensity of   withdrawal bleeding 
was more often normal or heavy in women treated with 
EE/LNG.7 The oral contraceptive composed of E2V/DNG is 
comparable to EE-containing oral contraceptive in terms of 
bleeding profile.7 Indeed, E2V/DNG showed an acceptable 
bleeding pattern and level of cycle control.
This novel oral contraceptive containing E2V and DNG 
is effective and well-tolerated,31 delivers stable levels of 
E2 throughout the cycle65 and is associated with a reduced 
impact on hemostatic and metabolic parameters compared 
with EE/LNG.7,38
In users of the DNG-containing oral contraceptives, the 
reduction in total and free protein S, and in t-PA and PAI 
was dependent on the EE dose, while factor VII activity 
was elevated, but not significantly different from that with 
EE/LNG.13 The levels of high-density lipoprotein cholesterol 
increased, while the levels of prothrombin fragment 1 + 2 
and D-dimer remained relatively unchanged; in contrast, the 
levels of SHBG, CBG and TBG increased.38
The finding that Qlaira® has a reduced metabolic impact 
when compared to EE/LNG-containing oral contraceptives, 
may attract particularly women aged over 35 years old or 
women with uncomplicated diabetes. Qlaira® may be very 
suitable also for women complaining of “estrogen withdrawal 
symptoms” such as headache or mood changes, because 
about 20% of women each month have no withdrawal bleed 
using Qlaira®.25
The Qlaira® regimen provides reliable contraceptive 
  efficacy7,29 and has been shown to be well tolerated,29 
with stable serum E2 levels maintained throughout the 
cycle.65
In fact, about 79.4% of women were satisfied with 
E2V/DNG.7,29
We have no data on the efficacy and tolerability of 
E2V/DNG in adolescents aged 18 years.3
Conclusion
The previous attempts to use natural estrogens, such as E2, 
for hormonal contraception were unsatisfactory in terms of 
cycle control because of the use of suboptimal doses of E2 
and of the inappropriate ratio of estrogen to   progestin. The 
natural E2 and the progestin DNG have been combined in 
a unique dynamic dosing regimen with four hormonal dos-
age steps in which estrogen and   progestin doses follow as 
closely as possible the menstrual cycle physiology. E2V/DNG 
is the best combination to guarantee a good control of the 
  menstrual cycle, together with high contraceptive safety, high 
  tolerability and a reduced metabolic impact.International Journal of Women’s Health 2010:2 289
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